26 results found.

Gastric Cancer Clinical Trial using GDC-0068; Placebo; mFOLFOX6

Genentech - Recruiting 18 years or older.
- A Randomized, Phase II, Placebo Controlled Study of GDC-0068, an Inhibitor to Akt, in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma.
GDC-0068; Placebo; mFOLFOX6

Gastric Cancer Clinical Trial using trastuzumab emtansine; taxane

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction.
trastuzumab emtansine; taxane

Gastric Adenocarcinoma Clinical Trial using Capecitabine; Oxaliplatin

Shanghai Zhongshan Hospital - Recruiting 18 years to 75 years.
- A Multicenter, Single Arm, Open-label Trial of Oxaliplatin Plus Capecitabine (XELOX) in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma.
Capecitabine; Oxaliplatin

Gastric Cancer Clinical Trial using trastuzumab [Herceptin]; Oxaliplatin; capecitabine; Radiation

Hoffmann-La Roche - Recruiting 18 years to 75 years.
- Safety and Tolerability of Oxaliplatin-Capecitabine-Trastuzumab Combination and Chemoradiotherapy in Adjuvant Setting in Operated HER2+ Patients With Gastric or Gastroesophageal Junction Adenocarcinoma: A Phase II Study (TOXAG Study).
trastuzumab [Herceptin]; Oxaliplatin; capecitabine; Radiation

Stomach Neoplasms Clinical Trial using AMG 337

Amgen - Recruiting 18 years or older.
- A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety, and Pharmacokinetics of AMG337 in Subjects With MET Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma or Other MET Amplified Solid Tumors.
AMG 337

Gastric Cancer Clinical Trial using Rilotumumab; Placebo

Amgen - Recruiting 18 years or older.
- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
Rilotumumab; Placebo

Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of t Clinical Trial using Ipilimumab; Best Supportive care (BSC)

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Randomized, Open-label, Two-arm Phase II Trial Comparing the Efficacy of Sequential Ipilimumab Versus Best Supportive Care Following First-line Chemotherapy in Subjects With Unresectable Locally Advanced/Metastatic Gastric or Gastro-esophageal Junction Cancer.
Ipilimumab; Best Supportive care (BSC)

Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesop Clinical Trial using oxaliplatin; leucovorin calcium; fluorouracil; therapeutic conventional surgery; radiation therapy; carboplatin; paclitaxel

Case Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase II Trial of Modified FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Response Based Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Adenocarcinoma of the Esophagus, Gastro-esophageal Junction, and Gastric Cardia.
oxaliplatin; leucovorin calcium; fluorouracil; therapeutic conventional surgery; radiation therapy; carboplatin; paclitaxel

Gastric Cancer Clinical Trial using Ramucirumab

Eli Lilly and Company - Recruiting 20 years or older.
- A Phase 2 Study of Ramucirumab in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First Line Platinum- or Fluoropyrimidine-Containing Combination Therapy in Japanese Patients.
Ramucirumab

Gastric Cancer Clinical Trial using RAD001

Chinese University of Hong Kong - Recruiting 18 years or older.
- Phase I/II Study of Paclitaxel / Carboplatin / RAD001 as First Line Therapy for Advanced Adenocarcinoma of the Stomach.
RAD001

Gastric Adenocarcinoma Clinical Trial using HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin; Curative gastrectomy

Hospices Civils de Lyon - Recruiting 18 years to 75 years.
- GASTRICHIP : D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma. A National Randomized and Multicentric Phase III Study..
HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin; Curative gastrectomy

Gastric Cancer Clinical Trial using Cabazitaxel

Krankenhaus Nordwest - Recruiting 18 years or older.
- Multicentre, Phase II Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Adenocarcinoma of the Oesophagogastric Junction and Stomach.
Cabazitaxel

Gastroesophageal Junction Adenocarcinoma, or Gastric Cancer Clinical Trial using Docetaxel, Leucovorin, Fluorouracil, Cisplatin; Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Patients With Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma.
Docetaxel, Leucovorin, Fluorouracil, Cisplatin; Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen

Metastatic or Recurrent Gastric Adenocarcinoma, or Her-2 Positive Clinical Trial using Herceptin+XELOX

Asan Medical Center - Recruiting 20 years or older.
- A Phase II Study of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer.
Herceptin+XELOX

Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cance Clinical Trial using FOLFOX regimen; docetaxel; fluorouracil; irinotecan hydrochloride; leucovorin calcium; oxaliplatin

Southwest Oncology Group - Recruiting 18 years or older.
- A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1(Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer.
FOLFOX regimen; docetaxel; fluorouracil; irinotecan hydrochloride; leucovorin calcium; oxaliplatin

Gastric Cancer Clinical Trial using TS-1, oxaliplatin

Samsung Medical Center - Recruiting 20 years or older.
- .
TS-1, oxaliplatin

Gastric Cancer Clinical Trial using albumin-bounded paclitaxel; S-1

Chinese Academy of Medical Sciences - Recruiting 18 years or older.
- Pase 2 Study of Albumin-bounded Paclitaxel Plus S-1 as First-line Chemotherapy for Locally Advanced or Metastatic Gastric or Gastro-esophageal Adenocarcinoma.
albumin-bounded paclitaxel; S-1

Gastric Adenocarcinoma Clinical Trial using Capecitabine, Oxaliplatin, Docetaxel

National Health Research Institutes, Taiwan - Recruiting 20 years or older.
- Using Genetic Polymorphisms of Drug Metabolism and Immunohistochemical Stain to Predict the Efficacy and Toxicity in Patients With Gastric Adenocarcinoma - A Phase II Study.
Capecitabine, Oxaliplatin, Docetaxel

Gastric Adenocarcinoma, or Esophageal Adenocarcinoma Clinical Trial using FLOT (5-fluorouracil, oxaliplatin, docetaxel)

McGill University - Recruiting 18 years or older.
- Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma.
FLOT (5-fluorouracil, oxaliplatin, docetaxel)

Gastric Cancer Clinical Trial using Oxaliplatin; Capecitabine

Harbin Medical University - Recruiting 65 years or older.
- A Randomized Single Center Phase II Study Comparing XELOX With Capecitabine Maintenance or XELOX Treatment in Elderly Metastatic Adenocarcinoma of Stomach.
Oxaliplatin; Capecitabine

Gastric Adenocarcinoma, Gastroesophageal Adenocarcinoma, or Dista Clinical Trial using Cabazitaxel

Weill Medical College of Cornell University - Recruiting 18 years or older.
- An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma.
Cabazitaxel

Gastric Adenocarcinoma Clinical Trial using Oxaliplatin+S-1; Adjuvant Oxaliplatin/S-1(SOX)

Chinese PLA General Hospital - Recruiting 20 years to 75 years.
- Phase III, Randomized, Multicenter, Controlled Evaluation of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Advanced Gastric Cancer Patients.
Oxaliplatin+S-1; Adjuvant Oxaliplatin/S-1(SOX)

Gastrointestinal Neoplasm, or Gastric Adenocarcinoma Clinical Trial using Irinotecan-Capecitabine-Oxaliplatin

AHS Cancer Control Alberta - Recruiting 18 years or older.
- A Multicentre, Open-label Phase II Study of Irinotecan, Capecitabine(Xeloda), and Oxaliplatin (IXO) as First Line Treatment in Patients With Metastatic Gastric or Gastroesophageal (GEJ) Adenocarcinoma..
Irinotecan-Capecitabine-Oxaliplatin

Gastric Adenocarcinoma Clinical Trial using S-1 and Oxaliplatin

Sixth Affiliated Hospital, Sun Yat-sen University - Recruiting 18 years to 75 years.
- A Phase II Trial Evaluate a Modified SOX Regimen in First-Line Treatment of Unresectable Gastric Adenocarcinoma.
S-1 and Oxaliplatin

Esophageal Adenocarcinoma, or Gastric Adenocarcinoma Clinical Trial using panitumumab, epirubicin, oxaliplatin, xeloda

Massachusetts General Hospital - Recruiting 18 years or older.
- A Pilot Study of Perioperative Panitumumab in Combination With Epirubicin, Oxaliplatin and Xeloda in Patients With Resectable Gastroesophageal Adenocarcinoma.
panitumumab, epirubicin, oxaliplatin, xeloda

Esophageal Neoplasms, or Stomach Neoplasms Clinical Trial using Docetaxel, Oxaliplatin; Radiotherapy

Johannes Gutenberg University Mainz - Recruiting 18 years to 75 years.
- Prospective, Open, Multicentre Phase I/II Study to Evaluate the Safety and Efficacy of a Neoadjuvant Radiochemotherapy With Docetaxel and Oxalipaltin in Patients With Adenocarcinoma of the Gastric-Oesophageal Junction.
Docetaxel, Oxaliplatin; Radiotherapy